Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
News|Videos|August 17, 2023
Ongoing Trials to Watch in Recurrent Endometrial Cancer
Author(s)Ruchi Garg, MD
Ruchi Garg, MD, discusses several important ongoing studies of targeted therapies in patients with recurrent endometrial cancer.
Advertisement
Advertisement
Related to this article
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Advertisement
Advertisement
Trending on Targeted Onc
1
Obrixtamig Shows Activity in First-Line epNEC, Regardless of DLL3 Expression Level
2
COA Backs 340B Payment Cut in 2027 Final Rules, Warns of Physician Cuts
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Radioligand Therapy Trials Begin Reshaping Neuroendocrine Tumor Care
5